Feng Zijian, executive vice president and secretary general of the Chinese Preventive Medicine Association, said that the real-world research on the preventive effect of domestic vaccines inoculated in Hong Kong and mainland China showed that Chinese vaccines still had a good protective effect on severe illness and death caused by Omicron mutant.
Feng Zijian introduced that at present, many technical routes in China have developed univalent and multivalent Omicron mutant vaccines. The univalent inactivated vaccine of Omicron mutant has been approved by clinical trials, and clinical trials are being carried out in Zhejiang, Hunan and Hongkong. The tetravalent recombinant protein vaccine, which has made rapid progress, has been approved for phase III clinical trial in UAE, and related research has been started. In addition, the research on broad-spectrum COVID-19 vaccine has been laid out, and the vaccine with rapid progress has been approved for clinical trials, and related research has been started.
Generally speaking, the research and development of Omicron mutant vaccine in China is progressing steadily and rapidly. As long as it is necessary and in accordance with the requirements of relevant laws and regulations, emergency use procedures can be quickly started to provide vaccination. As to whether and when to vaccinate the vaccine specifically targeting Omicron mutant, this issue is being studied not only in China but also internationally, mainly to judge the situation of virus mutation and immune escape. (Reporter Gu Tiancheng, Dong Ruifeng)
关于作者